ArticleJournal of human immunity2025
Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging.
Abstract read
In one paragraph
Article in Journal of human immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.Frontiers in immunology · 2025Pooled it
- Pretransplant immune dysregulation and survival after HSCT in pediatric inborn errors of immunity.Journal of human immunity · 2027Article
- JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function.Journal of human immunity · 2026Article
- How I Treat: Transplantation for primary immune regulatory diseases and inflammatory disorders.Journal of human immunity · 2026Article
- STAT1 gain-of-function in 12 Moroccan patients: Clinical and genetic insights.Journal of human immunity · 2026Article
- Fungal Infections in Disorders of Inborn Errors of Immunity.Clinical reviews in allergy & immunology · 2026Review
- Human CD21Journal of human immunity · 2026Review
- Genetic mechanisms underlying host susceptibility to central nervous system viral infections.Current opinion in infectious diseases · 2026Review
- TLR8 gain-of-function: on the highway to the danger zone.Blood advances · 2026Article
- Lymphoproliferation in Inborn Errors of Immunity: Mechanisms, Manifestations and Clinical Management, with a Focus on ALPID.ImmunoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Emilie Pauline BuddinghWillem-Alexander Children's Hospital, Department of Pediatrics, Pediatric Stem cell Transplantation program, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-2755-9408
Mary SlatterHaematopoietic Stem Cell Transplantation department, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle, United Kingdom.
Juan Carlos Aldave BecerraAllergy and Immunology, Hospital Rebagliati, Lima, Peru.
Laura Alonso GarciaPediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain.
Erik von AsmuthWillem-Alexander Children's Hospital, Department of Pediatrics, Pediatric Stem cell Transplantation program, Leiden University Medical Center, Leiden, The Netherlands.
Safa BarisDivision of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
Oscar de la Calle-MartínUniversitat Autònoma de Barcelona, Spain.
Alice Y ChanDepartment of Pediatrics, Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, United States of America.
Su-Wan Bianca ChanPaediatric Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore.
Shanmuganathan ChandrakasanAflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, United States of America.
Deepakbabu ChellapandianCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States of America.
Jasmeen DaraDepartment of Pediatrics, Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, United States of America.
Susan FarmandDivision of Pediatric Stem Cell Transplantation and Immunology, Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anders FasthQueen Silvia Children's Hospital, Gothenborg, Sweden.
Lisa Forbes SatterTexas Children's Hospital, Houston, Texas, Unites States of America.
Renata FormankovaUniversity Hospital in Motol, Prague, Czech Republic.
Eyal GrunebaumThe Hospital for Sick Children, Toronto, Canada.
Steven J KeoghChildren's Hospital at Westmead, Westmead, Australia.
Ayça Kiykimİstanbul Üniversitesi-Cerrahpaşa, Istanbul, Turkey.
Jörn-Sven KühlDepartment of Pediatrics, University Hospital Leipzig, Leipzig, Germany.
Alexandra LaberkoDepartment of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Timothy Ronan LeahyDepartment of Paediatric Immunology, Children's Health Ireland at Crumlin, Dublin, Ireland.
Caroline LindemansDepartment of Pediatric Immunology, University Medical Center, Utrecht, the Netherlands.
Caridad MartinezTexas Children's Hospital, Houston, Texas, Unites States of America.
Laura Martínez-MartínezUniversitat Autònoma de Barcelona, Spain.
William Glenn MitchellAflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, United States of America.
Emma MorrisUniversity College London, London, United Kingdom.
Joseph H OvedMemorial Sloan Kettering Cancer Centre, New York, United States of America.
Maria PolacikDepartment of Paediatrics and University Center for Rare Diseases, Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany.
Jacques G RivièrePediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain.
Chaim M RoifmanThe Hospital for Sick Children, Toronto, Canada.
Sara Sebnem KilicDivision of Pediatric Immunology, Bursa Uludag University, Bursa, Turkey.
Petr SedlacekUniversity Hospital in Motol, Prague, Czech Republic.
Ami J ShahStanford University, California, United States of America.
Linda VongThe Hospital for Sick Children, Toronto, Canada.
Arjan C LankesterWillem-Alexander Children's Hospital, Department of Pediatrics, Pediatric Stem cell Transplantation program, Leiden University Medical Center, Leiden, The Netherlands.
Michael H AlbertKinderklinik und Kinderpoliklinik, im Dr. von Haunerschen Kinderspital, Ludwig Maximilians Universität München, Munich, Germany.
Bénédicte NevenHopital Necker-Enfants Malades, Paris, France.
Troy TorgersonAllen Institute for Immunology, Seattle, Washington, United States of America.
Jennifer LeidingCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States of America.
Catharina SchuetzDepartment of Paediatrics and University Center for Rare Diseases, Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany.ORCID 0000-0001-8731-8924
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTraining of Clinical Investigators in Primary Immune DeficienciesU54AI082973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2009 to 2023
$23.3MSafety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutationsUH3TR003908 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI FORBES, LISA, TORGERSON, TROY R · 2024 to 2025
$1.7MSafety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutationsUG3TR003908 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI FORBES, LISA, TORGERSON, TROY R · 2021 to 2022
$1.2MUnraveling the Molecular Function of Mosaic, a gene mediating immune dysregulationK08AI137301 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAN, ALICE · 2019 to 2023
$1.0MUtilization of JAK inhibitor therapy in a transplant model of STAT1 GOF diseaseR21AI173539 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI FORBES, LISA · 2025 to 2025
$441kPrimary Immune Deficiency Treatment Consortium Annual Scientific MeetingR13AI094943 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2011 to 2025
$239kNCATS NIH HHS UG3 TR003908NCATS NIH HHS UH3 TR003908NCI NIH HHS P30 CA008748NIAID NIH HHS K08 AI137301NIAID NIH HHS R13 AI094943NIAID NIH HHS R21 AI173539NIAID NIH HHS U54 AI082973
Abstract
Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.